Apremilast oral suspension

Apremilast suspension formulations using specific ingredients achieve bioequivalent drug exposure and stability, addressing the need for pediatric-friendly dosage forms.

JP2024544720AInactive Publication Date: 2024-12-03AMGEN INC
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024536996
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2021-12-23
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is a need for alternative oral dosage forms of apremilast that provide clinically desirable drug exposure, particularly for pediatric patients who cannot swallow tablets.

Method used

Apremilast suspension formulations are developed using a combination of apremilast, a suspending agent (such as microcrystalline cellulose and sodium carboxymethyl cellulose), xanthan gum, sweeteners (like sucrose and sorbitol), glycerin, propylene glycol, citric acid, methylparaben, propylparaben, and water to create a stable and palatable suspension.

Benefits of technology

The suspension provides bioequivalent drug exposure to conventional tablets, is stable over 36 months at various conditions, and is well-tolerated, making it suitable for pediatric patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024544720000006
    Figure 2024544720000006
  • Figure 2024544720000007
    Figure 2024544720000007
  • Figure 2024544720000008
    Figure 2024544720000008
Patent Text Reader

Abstract

Provided herein is a suspension for oral administration comprising one or more of a) apremilast, b) a suspending agent, c) a sweetener, d) a vehicle, a co-solvent, a buffer, a preservative, or a combination thereof. Also provided herein is a suspension for oral administration comprising a) apremilast, b) microcrystalline cellulose / sodium carboxymethylcellulose, c) xanthan gum, d) sucrose, e) sorbitol, f) glycerin, g) propylene glycol, h) citric acid monohydrate, i) methylparaben, j) propylparaben, and k) water.
Need to check novelty before this filing date? Find Prior Art

Description

[Background technology]

[0001] Apremilast is a phosphodiesterase subtype IV ("PDE4") inhibitor that has been approved worldwide for the treatment of various diseases associated with inflammation. For example, in the United States, Apremilast is approved for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy, for the treatment of adult patients with active psoriatic arthritis, and for the treatment of adult patients with oral ulcers associated with Behcet's disease. Apremilast is the first and remains the only orally administered PDE4 inhibitor approved for the treatment of these inflammatory diseases. The recommended dosage for adult patients with active PsA and psoriasis is 30 mg orally twice daily (BID) after a 5-day titration intended to relieve gastrointestinal (GI) symptoms associated with initial treatment. Apremilast is still in clinical development for the treatment of additional inflammatory autoimmune disorders with elevated inflammatory cytokine levels.

[0002] Apremilast is currently being investigated in pediatric populations for psoriasis vulgaris, psoriatic arthritis (e.g., juvenile PsA) and Behcet's disease. However, there is a need for an apremilast formulation that is easy to swallow and administer to ensure patient compliance and is suitable for use in certain patient populations, such as pediatric patients. Thus, an apremilast suspension formulation is needed to administer apremilast tablets to pediatric subjects who cannot swallow them. Summary of the Invention [Problem to be solved by the invention]

[0003] In view of the above, there remains a need for alternative oral dosage forms of apremilast that provide clinically desirable drug exposure. [Means for solving the problem]

[0004] The present disclosure provides a suspension for oral administration comprising: a) apremilast; b) a suspending agent; c) a sweetener; d) one or more of a vehicle, co-solvent, buffer, preservative, or combinations thereof; and e) water.

[0005] The present disclosure also provides a suspension for oral administration comprising a) apremilast, b) a blend of microcrystalline cellulose and sodium carboxymethylcellulose, c) xanthan gum, d) sucrose, e) sorbitol, f) glycerin, g) propylene glycol, h) citric acid monohydrate, i) methylparaben, j) propylparaben, and k) water. [Brief description of the drawings]

[0006] [Figure 1] 1 shows the mean apremilast plasma concentration time profile between the oral suspension and conventional tablets (linear scale). [Diagram 2] 1 shows the mean apremilast plasma concentration time profiles between the oral suspension and conventional tablets (semi-log scale). [Diagram 3] Mean Apremilast plasma concentration time profile (effect of food) oral suspension is shown (linear scale). [Figure 4] Mean Apremilast plasma concentration time profile (food effect) oral suspension is shown (semi-log scale). [Figure 5A] 1 shows assay results from a stability study of the disclosed suspension over 36 months at 25° C. and 60% relative humidity. [Figure 5B] 1 shows total degradant results from stability studies of the disclosed suspensions over 36 months at 25° C. and 60% relative humidity. [Figure 5C] 1 shows methylparaben content results from stability studies of the disclosed suspensions over 36 months at 25° C. and 60% relative humidity. [Figure 5D] 1 shows propylparaben content results from stability studies of the disclosed suspensions over 36 months at 25° C. and 60% relative humidity. [Figure 5E]1 shows viscosity results from a stability study of the disclosed suspension over 36 months at 25° C. and 60% relative humidity. [Figure 5F] 1 shows density results from stability studies of the disclosed suspensions over 36 months at 25° C. and 60% relative humidity. [Figure 5G] 1 shows pH results from a stability study of the disclosed suspension over 36 months at 25° C. and 60% relative humidity. [Figure 5H] 1 shows assay results from a stability study of the disclosed suspension over 6 months at 40° C. and 75% relative humidity. [Figure 5I] 1 shows assay results from degradation products from stability studies of the disclosed suspensions over 6 months at 40° C. and 75% relative humidity. [Figure 5J] 1 shows methylparaben content results from stability studies of the disclosed suspensions over 6 months at 40° C. and 75% relative humidity. [Figure 5K] 1 shows propylparaben content results from a stability study of the disclosed suspensions over 6 months at 40° C. and 75% relative humidity. [Figure 5L] 1 shows viscosity results from a stability study of the disclosed suspension over 6 months at 40° C. and 75% relative humidity. [Figure 5M] 1 shows density results from a stability study of the disclosed suspensions over 6 months at 40° C. and 75% relative humidity. [Figure 5N] 1 shows density results from a stability study of the disclosed suspensions over 6 months at 40° C. and 75% relative humidity. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0007] Provided herein is a suspension for oral administration comprising: a) apremilast; b) a suspending agent; c) a sweetener; d) one or more of a vehicle, co-solvent, buffer, preservative or mixtures thereof; and e) water.

[0008] In some embodiments, the disclosure provides a suspension for oral administration comprising a) apremilast, b) microcrystalline cellulose / sodium carboxymethylcellulose, c) xanthan gum, d) sucrose, e) sorbitol, f) glycerin, g) propylene glycol, h) citric acid monohydrate, i) methylparaben, j) propylparaben, and k) water, as described herein. In some embodiments, the suspension contains a) 5 mg / mL apremilast, b) 6.7 mg / mL microcrystalline cellulose / sodium carboxymethylcellulose, c) 1.8 mg / mL xanthan gum, d) 190 mg / mL sucrose, e) 190 mg / mL sorbitol, f) 133 mg / mL glycerin, g) 14 mg / mL propylene glycol, h) 1.8 mg / mL citric acid monohydrate, i) 1.5 mg / mL methylparaben, j) 0.17 mg / mL propylparaben, and k) water, as described herein.

[0009] The disclosed suspensions have an area under the curve (AUC) equivalent to that of an immediate release oral apremilast tablet of comparable apremilast strength (e.g., bioequivalence). In some embodiments, the suspensions have an area under the curve (AUC) of 80% to 125% or 90% to 110% of that of an immediate release oral apremilast tablet of comparable apremilast strength when administered to a patient under fasting conditions.

[0010] Apremilast The disclosed suspension contains a suitable amount (e.g., concentration) of apremilast. Desirably, the suspension contains an amount of apremilast suitable for providing an area under the curve (AUC) (e.g., bioequivalence) equivalent to that of an immediate release oral apremilast tablet of equivalent apremilast content. If the suspension contains too little apremilast, the suspension will not deliver a clinically relevant amount of apremilast and will not be effective when administered. Conversely, if the suspension contains too much apremilast, the suspension will be inefficient in the use of apremilast, too costly, and / or not optimal for the intended patient population (e.g., pediatric patients), and / or may induce adverse events. In some embodiments, apremilast is present in the suspension at a total concentration of 3 to 10 mg / mL (e.g., 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, or 10.0 mg / mL of apremilast, and any range defined by any two of these values). In some embodiments, apremilast is present in the suspension at a total concentration of 5 mg / mL.

[0011] Suspending Agent The disclosed suspension comprises a suspending agent. The suspending agent can be any suitable suspending agent. Some contemplated suspending agents include, but are not limited to, commercially available suspending agents such as microcrystalline cellulose, sodium carboxymethylcellulose, xanthan gum, hypromellose, polyvinylpyrrolidone (PVP) and blends of microcrystalline cellulose and sodium carboxymethylcellulose, such as Avicel® RC-591 or Avicel® CL-611. In some embodiments, the suspending agent comprises microcrystalline cellulose, sodium carboxymethylcellulose, methylcellulose, ethylcellulose, xanthan gum, xanthin gum, carrageenan; guar gum, locust bean gum, carbomer, magnesium aluminum silicate (Veegum), or combinations thereof. In some embodiments, the suspending agent comprises a blend of microcrystalline cellulose and sodium carboxymethylcellulose and xanthan gum. In some embodiments, the suspending agent comprises xanthan gum.

[0012] The disclosed suspensions include a suitable amount of suspending agent. If the suspension includes too little suspending agent, the suspension may lack stability. If the suspension includes too much suspending agent, the suspension may not have the desired physical properties (e.g., be too viscous). In some embodiments, the suspending agent may be present in a total concentration of 5 mg / mL to 10 mg / mL (e.g., 5, 6, 7, 8, 9, or 10 mg / mL and any range defined by any two of these values). In some embodiments, the suspending agent is present in the suspension at a total concentration of 8.5 mg / mL.

[0013] In some embodiments, the suspension comprises two or more suspending agents. In embodiments in which two or more suspending agents are present, each of the suspending agents may be present in the same or different amounts. For example, in some embodiments in which the suspending agents comprise a microcrystalline cellulose / sodium carboxymethylcellulose blend and xanthan gum, the microcrystalline cellulose / sodium carboxymethylcellulose blend and xanthan gum are present in a concentration ratio of less than 4 to 1 (e.g., 4:1, 3.9:1, 3.8:1, 3.7:1, 3.6:1, 3.5:1, 3.4:1, 3.3:1, 3.2:1, 3.1:1, or 3:1 and any range defined by any two of these values). By way of example, in some embodiments, the microcrystalline cellulose / sodium carboxymethylcellulose blend and xanthan gum are present in a concentration ratio of 3:4:1 to 4:1 (e.g., 3:5:1 to 3.9:1 or 3:6:1 to 3.8:1). In some embodiments, the microcrystalline cellulose / sodium carboxymethylcellulose blend and xanthan gum are present in a concentration ratio of 3.7: 1. In some embodiments, the microcrystalline cellulose / sodium carboxymethylcellulose blend is present in the suspension at a total concentration of 6.7 mg / mL and the xanthan gum is present in the suspension at a total concentration of 1.8 mg / mL.

[0014] sweetener The disclosed suspensions include a sweetener. The sweetener can be any suitable sweetener. It is understood that the selection of the sweetener and any other ingredients is compatible with the desired patient population. For example, if the suspension is intended for a pediatric population, a suitable ingredient (e.g., a sweetener) is used, and the sweetener is one that is compatible with the pediatric population. Desirably, the sweetener improves palatability. Non-limiting examples of contemplated sweeteners include sucrose, dextrose, maltose, dextrin, trehalose, fructose, levulose, galactose, sorbitol, mannitol, xylose, hydrogenated starch hydrolysates, maltitol, isomalt, erythritol, and lactitol. In some embodiments, the sweetener comprises sucrose, sorbitol, aspartame, fructose, lactose, or a combination thereof. In some embodiments, the sweetener comprises sucrose and sorbitol.

[0015] The disclosed suspension comprises a suitable amount of sweetener. If the suspension comprises too little sweetener, the suspension may have a bitter taste and / or a too low viscosity. Alternatively or additionally, if the suspension comprises too much sweetener, the suspension may be too sweet and / or have a too high viscosity, resulting in an unpleasant taste. In some embodiments, the sweetener is present in the suspension at a total concentration of 500 mg / mL or less (e.g., 500, 490, 480, 470, 460, 450, 440, 430, 420, 410, 400, 390, 380, 370, 360, 350, 340, 330, 320, 310, 300, 290, 280, 270, 260, 250, 240, 230, 220, 210, or 200 mg / mL of sweetener and any range defined by any two of these values). In some embodiments, the sweetener is present in the suspension at a total concentration of 380 mg / mL.

[0016] In some embodiments, the suspension comprises two or more sweeteners. In these embodiments, each of the sweeteners is present in a suitable amount. For example, in some embodiments where the sweetener comprises sucrose and sorbitol, the sweetener comprises sucrose at a concentration of 150-225 mg / mL and sorbitol at a concentration of 150-225 mg / mL. Non-limiting concentrations for sucrose or sorbitol include, for example, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, or 225 mg / mL and any range defined by any two of these values. For example, in some embodiments, the suspension comprises 190 mg / mL sucrose and 190 mg / mL sorbitol (liquid), i.e., a 1:1 concentration ratio of sucrose to sorbitol.

[0017] Vehicle In some embodiments, the disclosed suspensions include a vehicle. Desirably, the vehicle stabilizes the suspension and helps minimize particle settling. In some embodiments, the vehicle is used to reduce the hydration time of the suspending agent. In some embodiments, the vehicle can be used to disperse the active ingredient. In some embodiments, the vehicle includes glycerin.

[0018] The disclosed suspensions, when present, include a suitable amount of vehicle. If the suspension includes too little vehicle, the suspension may not be stable. Alternatively or additionally, if the suspension includes too much vehicle, the suspension may have unsuitable properties (e.g., too viscous). In some embodiments, the vehicle is present in the suspension at a total concentration of 100 mg / mL to 200 mg / mL (e.g., 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, or 200 mg / mL of vehicle and any range defined by any two of these values). In some embodiments, the vehicle is present in the suspension at a total concentration of 133 mg / mL.

[0019] Co-solvents In some embodiments, the disclosed suspensions include a co-solvent. Desirably, the co-solvent improves the solubility of the preservatives (e.g., methyl and propyl parabens) in the suspension and helps improve stability. In some embodiments, the co-solvent includes propylene glycol.

[0020] The disclosed suspensions, when present, contain a suitable amount of co-solvent. If the suspension contains too little or too much co-solvent, the suspension may lack the desired physical properties and shortened shelf life. In some embodiments, the co-solvent is present in the suspension at a total concentration of 10 mg / mL to 20 mg / mL (e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mg / mL of co-solvent and any range defined by any two of these values). In some embodiments, the co-solvent is present in the suspension at a total concentration of 14 mg / mL.

[0021] In some embodiments, the co-solvent is heated to 40° C.-50° C. to decrease the elution time.

[0022] Buffer In some embodiments, the disclosed suspension comprises a buffering agent. Non-limiting examples of contemplated buffering agents include acetic acid, ammonium carbonate, ammonium phosphate, boric acid, citric acid (e.g., anhydrous citric acid or citric acid monohydrate), lactic acid, phosphoric acid, citrate salts (e.g., potassium citrate or sodium citrate), potassium metaphosphate, dibasic potassium phosphate, potassium dihydrogen phosphate, sodium acetate, sodium lactate, dibasic sodium phosphate, sodium dihydrogen phosphate, and succinic acid. In some embodiments, the buffering agent comprises citric acid (e.g., citric acid monohydrate) or a salt thereof (e.g., potassium citrate or sodium citrate), or a combination thereof. In some embodiments, the buffering agent comprises citric acid or a hydrate thereof, a citrate salt, a tartaric acid, a tartrate salt, an ascorbic acid, an ascorbate salt, a phosphoric acid, a phosphoric acid salt, an acetic acid, an acetate salt, or a combination thereof. In some embodiments, the buffering agent comprises citric acid monohydrate.

[0023] The disclosed suspensions, when present, contain a suitable amount of buffering agent. If the suspension contains too little buffering agent, the suspension may not have a desired pH. Alternatively or additionally, if the suspension contains too much buffering agent, the suspension may lack stability. In some embodiments, the buffering agent is present in the suspension at a total concentration of 1 mg / mL to 5 mg / mL (e.g., 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, or 5.0 mg / mL of buffering agent and any range defined by any two of these values). For example, in some embodiments, the buffering agent is present in the suspension at a total concentration of 1.6 mg / mL to 2 mg / mL. In some embodiments, the buffering agent is present in the suspension at a total concentration of 1.8 mg / mL.

[0024] Preservatives In some embodiments, the disclosed suspensions include a preservative. Contemplated preservatives include, but are not limited to, antimicrobial agents, antioxidants, and agents that maintain stability and prevent microbial growth. Exemplary preservatives include, but are not limited to, ascorbic acid, ascorbyl palmitate, benzyl alcohol, xylitol, butyl hydroxyanisole (BHA), butyl hydroxytoluene (BHT), citric acid, erythorbic acid, fumaric acid, malic acid, propyl gallate, sodium ascorbate, sodium benzoate, sodium bisulfate, sodium metabisulfite, sodium sulfite, parabens (e.g., methyl-, ethyl-, butyl-), benzoic acid, potassium sorbate, and vanillin. In some embodiments, the preservative includes methylparaben, propylparaben, or a combination thereof. In some embodiments, the preservative includes methylparaben and propylparaben.

[0025] The disclosed suspensions, when present, include a suitable amount of preservative. If the suspension includes too little preservative, the suspension may not have microbial stability. Alternatively or additionally, if the suspension includes too much preservative, the suspension may taste bitter. In some embodiments, the preservative is present in the suspension at a total concentration of 0.5 mg / mL to 2.5 mg / mL (e.g., 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, or 2.5 mg / mL of preservative and any range defined by any two of these values). In some embodiments, the preservative is present in the suspension at a total concentration of 1 mg / mL to 2.5 mg / mL. In some embodiments, the preservative is present in the suspension at a total concentration of 1.7 mg / mL. In some embodiments, the preservative is present in the suspension at a total concentration of 1.5 mg / mL. In some embodiments, the preservative is present in the suspension at a total concentration of 1.2 mg / mL. In some embodiments, the preservative is present in the suspension at a total concentration of 1.1 mg / mL. In some embodiments, the preservative is present in the suspension at a total concentration of 0.9 mg / mL.

[0026] In some embodiments, the suspension includes two or more preservatives. In these embodiments, each of the preservatives is present in a suitable amount. For example, in some embodiments, the suspension includes methylparaben and propylparaben. In some embodiments where the preservatives include methylparaben and propylparaben, the concentration ratio of methylparaben to propylparaben is 9 to 1. In some embodiments where the preservatives include methylparaben and propylparaben, methylparaben is present at a concentration of 0.9 mg / mL or more and propylparaben is present at a concentration of 0.1 mg / mL or more. In some embodiments where the suspension includes methylparaben and propylparaben, methylparaben is present at a concentration of 0.9 mg / mL and propylparaben is present at a concentration of 0.1 mg / mL. In some embodiments where the suspension includes methylparaben and propylparaben, methylparaben is present at a concentration of 1.5 mg / mL and propylparaben is present at a concentration of 0.17 mg / mL. In some embodiments containing methylparaben and propylparaben, methylparaben is present at a concentration of 1.1 mg / mL and propylparaben is present at a concentration of 0.12 mg / mL. In some embodiments containing methylparaben and propylparaben, methylparaben is present at a concentration of 1.2 mg / mL and propylparaben is present at a concentration of 0.14 mg / mL.

[0027] water The disclosed suspension comprises water.The suspension comprises a suitable amount of water in the desired total volume of suspension to obtain the desired concentration of components as described herein.In some embodiments, the suspension comprises enough water to provide a suspension with a total volume of 1 mL.In some embodiments, the suspension comprises enough water to provide a suspension with a total volume of 6 mL.

[0028] Treatment method In some embodiments, the present disclosure provides a method of treating a patient suffering from a disease or disorder ameliorated by inhibiting PDE4, comprising administering to the patient a suspension as disclosed herein. In some embodiments, the patient is an adult patient. In some embodiments, the patient is a pediatric patient.

[0029] In some embodiments, the disease or disorder is psoriasis, psoriatic arthritis, or Behcet's disease.

[0030] The present disclosure provides a method of treating a patient suffering from a disease or disorder ameliorated by inhibiting PDE4 comprising administering to the patient a suspension disclosed herein.

[0031] In some embodiments, the disease or disorder is asthma, arthritis, psoriasis, inflammation, chronic or acute obstructive pulmonary disease, chronic or acute inflammatory pulmonary disease, cutaneous lupus erythematosus, palmoplantar pustulosis, inflammatory bowel disease, Crohn's disease, Behcet's disease, or ulcerative colitis. In some embodiments, the disease or disorder is arthritis. In some embodiments, the arthritis is psoriatic arthritis. In some embodiments, the disease or disorder is psoriasis. In some embodiments, the disease or disorder is ulcerative colitis. In some embodiments, the disease or disorder is Behcet's disease.

[0032] In some embodiments, the disclosed suspension is administered with a twice-daily apremilast formulation (e.g., tablet formulation) after initial titration. In some embodiments, the method includes administering only the disclosed suspension. In embodiments where only the disclosed suspension is administered, any initial titration is performed with the disclosed suspension at a suitable dosage strength.

[0033] In some embodiments, the disclosed methods include the following initial titration schedule: (i) a suspension having 10 mg of apremilast in the morning on day 1 of dosing; (ii) 10 mg in the morning and 10 mg in the afternoon on day 2 of dosing; (iii) 10 mg in the morning and 20 mg in the afternoon on day 3 of dosing; (iv) 20 mg in the morning and 20 mg in the afternoon on day 4 of dosing; (v) 20 mg in the morning and 30 mg in the afternoon on day 5 of dosing; and (vi) 30 mg of apremilast twice daily on day 6 of dosing and every day thereafter.

[0034] In some embodiments, the disclosed methods include the following initial titration schedule: (i) 10 mg in the morning on day 1 of dosing; (ii) 10 mg in the morning and 10 mg in the afternoon on day 2 of dosing; (iii) 10 mg in the morning and 20 mg in the afternoon on day 3 of dosing; (iv) 20 mg in the morning and 20 mg in the afternoon on day 4 of dosing; (v) 20 mg in the morning and 30 mg in the afternoon on day 5 of dosing; and (vi) 30 mg in the morning and 30 mg in the afternoon on days 6-14 of dosing; and on day 15 and every day thereafter, a disclosed suspension having 30 mg of apremilast twice daily.

[0035] In some embodiments, the disclosed methods include the following initial titration schedule (e.g., using a twice-daily tablet formulation): (i) 10 mg in the morning on day 1 of administration; (ii) 10 mg in the morning and 10 mg in the afternoon on day 2 of administration; (iii) 10 mg in the morning and 20 mg in the afternoon on day 3 of administration; (iv) 20 mg in the morning and 20 mg in the afternoon on day 4 of administration; (v) 20 mg in the morning and 30 mg in the afternoon on day 5 of administration; and (vi) a suspension as disclosed herein having 30 mg of apremilast twice daily on days 6 and thereafter.

[0036] In some embodiments, the disclosed methods include the following initial titration schedule: (i) 10 mg in the morning on day 1 of administration; (ii) 10 mg in the morning and 10 mg in the afternoon on day 2 of administration; (iii) 10 mg in the morning and 20 mg in the afternoon on day 3 of administration; and (iv) 20 mg of apremilast twice daily on days 4 and thereafter.

[0037] In some embodiments, the disclosed methods include the following initial titration schedule: (i) 10 mg in the morning on day 1 of dosing; (ii) 10 mg in the morning and 10 mg in the afternoon on day 2 of dosing; (iii) 10 mg in the morning and 20 mg in the afternoon on day 3 of dosing; (iv) 20 mg in the morning and 20 mg in the afternoon on days 4-14; and (v) on days 15 and thereafter, a suspension as disclosed herein having 20 mg of apremilast twice daily.

[0038] In some embodiments, the disclosed methods include the following initial titration schedule: (i) a suspension having 5 mg of apremilast in the morning on dose day 1; (ii) 5 mg in the morning and 5 mg in the afternoon on dose day 2; (iii) 5 mg in the morning and 10 mg in the afternoon on dose day 3; (iv) 10 mg in the morning and 10 mg in the afternoon on dose day 4; (v) 10 mg in the morning and 20 mg in the afternoon on dose day 5; (vi) 20 mg twice daily on dose day 6 and every day thereafter.

[0039] In some embodiments, the present disclosure provides a packaged suspension comprising the suspension disclosed herein, a bottle, and a stopper.

[0040] Embodiment 1. A suspension for oral administration, comprising: Apremilast, b. a suspending agent; C. a sweetener; d. one or more of a vehicle, a co-solvent, a buffer, a preservative, or a combination thereof; e. Water and A suspension comprising: 2. The suspension of embodiment 1, wherein apremilast is present in the suspension in a total concentration of 3 to 10 mg / mL. 3. The suspension of embodiment 2, wherein apremilast is present in the suspension at a total concentration of 5 mg / mL. 4. The suspension of any one of embodiments 1 to 3, wherein the suspending agent comprises microcrystalline cellulose, sodium carboxymethylcellulose, methylcellulose, ethylcellulose, xanthan gum, xanthin gum, carrageenan; guar gum, locust bean gum, carbomer, magnesium aluminum silicate (Veegum), or combinations thereof. 5. The suspension of embodiment 4, wherein the suspending agent comprises a blend of microcrystalline cellulose and sodium carboxymethylcellulose (microcrystalline cellulose / sodium carboxymethylcellulose blend) and xanthan gum. 6. The suspension of embodiment 5, wherein the microcrystalline cellulose / sodium carboxymethylcellulose blend and xanthan gum are present in a concentration ratio of 3.4:1 to 4:1 or less. 7. The suspension of embodiment 6, wherein the ratio is 3.7:1. 8. The suspension of any one of the preceding embodiments, wherein the suspension is present in the suspension at a total concentration of 8.5 mg / mL. 9. The suspension of any one of embodiments 1 to 8, wherein the sweetener comprises sucrose, sorbitol, aspartame, fructose, lactose or a combination thereof. 10. The suspension of embodiment 9, wherein the sweetener comprises sucrose and sorbitol. 11. The suspension according to embodiment 9 or 10, wherein the sweetener is present in the suspension in a total concentration of less than or equal to 500 mg / mL. 12. The suspension of embodiment 11, wherein the sweetener is present in the suspension at a total concentration of 380 mg / mL. 13. The suspension according to any one of the preceding embodiments, wherein the sweetener comprises sucrose in a concentration of 150 to 225 mg / mL and sorbitol in a concentration of 150 to 225 mg / mL. 14. The suspension of embodiment 13, wherein the sweetener comprises sucrose and sorbitol in a 1:1 concentration ratio. 15. The suspension according to any one of the preceding embodiments, wherein the suspension comprises a vehicle. 16. The suspension of embodiment 15, wherein the vehicle comprises glycerin. 17. The suspension according to embodiment 15 or 16, wherein the vehicle is present in the suspension in a total concentration of 100 mg / mL to 200 mg / mL. 18. The suspension of embodiment 17, wherein the vehicle is present in a total concentration of 133 mg / mL. 19. The suspension according to any one of the preceding embodiments, wherein the suspension comprises a co-solvent. 20. The suspension of embodiment 19, wherein the co-solvent comprises propylene glycol. 21. The suspension according to embodiment 19 or 20, wherein the co-solvent is present in the suspension in a total concentration from 10 mg / mL to 20 mg / mL. 22. The suspension of embodiment 21, wherein the co-solvent is present in a total concentration of 14 mg / mL. 23. The suspension according to any one of the preceding embodiments, wherein the suspension comprises a buffer. 24. The suspension of embodiment 23, wherein the buffering agent comprises citric acid or a hydrate thereof, a citrate salt, tartaric acid, a tartrate salt, ascorbic acid, an ascorbate salt, phosphoric acid, a phosphate salt, acetic acid, an acetate salt, or a combination thereof. 25. The suspension of embodiment 24, wherein the buffering agent comprises citric acid monohydrate. 26. The suspension according to any one of embodiments 23-25, wherein the buffering agent is present in the suspension in a total concentration of 1 mg / mL to 5 mg / mL. 27. The suspension of embodiment 26, wherein the buffering agent is present in a total concentration of 1.8 mg / mL. 28. The suspension according to any one of the preceding embodiments, wherein the suspension comprises a preservative. 29. The suspension of embodiment 28, wherein the preservative comprises methylparaben, propylparaben, or a combination thereof. 30. The suspension of embodiment 29, wherein the preservatives include methylparaben and propylparaben. 31. The suspension of embodiment 30, wherein methylparaben and propylparaben are present in a concentration ratio of 9 to 1. 32. The suspension according to any one of embodiments 28-31, wherein the preservative is present in the suspension in a total concentration between 1 mg / mL and 2.5 mg / mL. 33. The suspension of embodiment 32, wherein the preservative is present in a total concentration of 1.7 mg / mL. 34. The suspension of any one of embodiments 30-32, wherein methylparaben is present in a concentration of 0.9 mg / mL or more, and propylparaben is present in a concentration of 0.1 mg / mL or more. 35. A suspension for oral administration comprising a) apremilast, b) a blend of microcrystalline cellulose and sodium carboxymethylcellulose, c) xanthan gum, d) sucrose, e) sorbitol, f) glycerin, g) propylene glycol, h) citric acid monohydrate, i) methylparaben, j) propylparaben, and k) water. 36. The suspension of embodiment 35 comprising a) 5 mg / mL apremilast, b) 6.7 mg / mL of a blend of microcrystalline cellulose and sodium carboxymethylcellulose, c) 1.8 mg / mL xanthan gum, d) 190 mg / mL sucrose, e) 190 mg / mL sorbitol, f) 133 mg / mL glycerin, g) 14 mg / mL propylene glycol, h) 1.8 mg / mL citric acid monohydrate, i) 1.5 mg / mL methylparaben, j) 0.17 mg / mL propylparaben, and k) water. 37. The suspension of embodiment 35 comprising a) 5 mg / mL apremilast, b) 6.7 mg / mL of a blend of microcrystalline cellulose and sodium carboxymethylcellulose, c) 1.8 mg / mL xanthan gum, d) 190 mg / mL sucrose, e) 190 mg / mL sorbitol, f) 133 mg / mL glycerin, g) 14 mg / mL propylene glycol, h) 1.8 mg / mL citric acid monohydrate, i) 0.9 mg / mL methylparaben, j) 0.10 mg / mL propylparaben, and k) water. 38. The suspension of embodiment 35 comprising a) 5 mg / mL apremilast, b) 6.7 mg / mL of a blend of microcrystalline cellulose and sodium carboxymethylcellulose, c) 1.8 mg / mL xanthan gum, d) 190 mg / mL sucrose, e) 190 mg / mL sorbitol, f) 133 mg / mL glycerin, g) 14 mg / mL propylene glycol, h) 1.8 mg / mL citric acid monohydrate, i) 1.1 mg / mL methylparaben, j) 0.12 mg / mL propylparaben, and k) water. 39. The suspension of embodiment 35 comprising a) 5 mg / mL apremilast, b) 6.7 mg / mL of a blend of microcrystalline cellulose and sodium carboxymethylcellulose, c) 1.8 mg / mL xanthan gum, d) 190 mg / mL sucrose, e) 190 mg / mL sorbitol, f) 133 mg / mL glycerin, g) 14 mg / mL propylene glycol, h) 1.8 mg / mL citric acid monohydrate, i) 1.2 mg / mL methylparaben, j) 0.14 mg / mL propylparaben, and k) water. 40. A suspension according to any one of embodiments 1-39, which, when administered to a patient under fasting conditions, has an AUC that is 90% to 110% of the AUC of an immediate release oral apremilast tablet of equivalent apremilast content. 41. A method for treating a patient suffering from a disease or disorder that is ameliorated by inhibiting PDE4, comprising administering to the patient a suspension described in any one of embodiments 1 to 40. 42. The method of embodiment 41, wherein the disease or disorder is psoriasis, psoriatic arthritis or Behcet's disease. 43. The method of embodiment 41 or 42, wherein the patient is a pediatric patient. 44. A packaged suspension comprising the suspension according to any one of embodiments 1 to 40, a bottle, and a stopper. EXAMPLES

[0041] The following examples further illustrate the disclosed methods of treatment but, of course, should not be construed as in any way limiting their scope.

[0042] In the examples, the following abbreviations are used: AUC 0-∞ refers to the area under the plasma concentration curve calculated from time 0 to infinity; AUC 0-t refers to the area under the concentration-time curve calculated from time 0 of administration to the time of the last acquisition; CL / F refers to the apparent total body clearance of the drug calculated after extravascular administration; C max refers to the highest concentration observed; C trough refers to the plasma concentration observed at the end of the dosing interval; CI refers to the confidence interval; CV% refers to the coefficient of variation; t 1 / 2 refers to the terminal half-life; t lag refers to the delay between the time of administration and the onset of the absorption lag time; T max is C max Vz / F refers to the time to reach the terminal phase; Vz / F refers to the apparent volume of distribution during the terminal phase; F refers to the relative bioavailability of the oral suspension formulation compared to the tablet formulation.

[0043] F rel1 F refers to the relative bioavailability of each test formulation compared to the reference formulation; rel2 refers to the relative bioavailability of each dose-corrected test formulation compared to the dose-corrected reference formulation IR tablet.

[0044] Example 1 This example illustrates a compounding process for preparing an oral suspension of apremilast according to an embodiment of the present disclosure.

[0045] Sucrose (extra fine) and sorbitol liquid were added to purified water and mixed thoroughly to produce a sweetener solution. Microcrystalline cellulose / sodium carboxymethylcellulose and xanthan gum were added to the sweetener solution with mixing to obtain a homogeneous suspension. In a separate vessel, methylparaben and propylparaben were dissolved in propylene glycol. Optionally, the mixture of methylparaben and propylparaben can be heated (e.g., up to 60°C) to facilitate dissolution. After dissolution, the solution was cooled to room temperature. The paraben solution was then added to the previously prepared homogeneous suspension with mixing, along with citric acid monohydrate. The resulting suspension was then passed through an appropriate size mesh (e.g., 20 mesh). In a separate vessel, apremilast API was screened and dispersed in glycerin. The glycerin suspension was then mixed with the sieved suspension containing the other components. Purified water was added (amount appropriate) to provide a bulk suspension with the desired volume, and the bulk suspension was mixed.

[0046] The filler surge tank was filled with the bulk suspension with mixing prior to and during the filling process. Glass bottles were filled to the desired target weight (± 5%). Necessary process controls (e.g., checking fill volume) were performed. Caps were attached to the filled glass bottles.

[0047] Example 2 This example illustrates the stability of the disclosed oral suspension under various conditions and times, including accelerated stability testing conditions (e.g., 60% RH at 5° C., 25° C., and 75% RH at 40° C.) for up to 36 months.

[0048] A suspension was prepared containing: 5 mg apremilast, 190 mg sucrose, 190 mg sorbitol, 133 mg glycerin, 6.7 mg MCC, 1.8 mg xanthan gum, 1.8 mg citric acid, 1.5 mg methylparaben, 0.172 mg propylparaben, 14 mg propylene glycol, and purified water (qs to 1 mL). The suspension was packaged in an amber glass bottle.

[0049] The suspensions were evaluated using standard methods for the following properties: appearance; resuspendability; assay; methylparaben; propylparaben; degradation products; pH; microbial limits; container appearance; density; and viscosity.

[0050] When stored at 5°C, the suspension consistently met stability criteria at all time points over a one-month period.

[0051] When stored at 25°C / 60% RH, the suspensions consistently met the acceptance criteria for stability at all time points up to 36 months. Although signs of settling were present starting at 6 months and continuing through 36 months, the resuspension of the suspensions was within 10 seconds of specification throughout the laboratory, regardless of storage conditions. Additionally, when stored at 40°C / 75% RH, the suspensions consistently met the acceptance criteria for stability at all time points up to 6 months.

[0052] These results are summarized in Figures 5A-5G, where the data demonstrate that the disclosed suspension has a shelf life of 36 months when stored at or below 25°C.

[0053] Example 3 This example demonstrates the bioavailability of a single oral dose of 6 mL (30 mg) of apremilast oral suspension compared to apremilast 30 mg tablets in healthy subjects. This example also demonstrates the effect of food on the pharmacokinetics of the disclosed suspension. The oral suspension contained a) 5 mg / mL apremilast, b) 6.7 mg / mL of a blend of microcrystalline cellulose and sodium carboxymethylcellulose, c) 1.8 mg / mL xanthan gum, d) 190 mg / mL sucrose, e) 190 mg / mL sorbitol, f) 133 mg / mL glycerin, g) 14 mg / mL propylene glycol, h) 1.8 mg / mL citric acid monohydrate, i) 1.5 mg / mL methylparaben, j) 0.17 mg / mL propylparaben, and k) water. Apremilast 30 mg tablets contained 30 mg apremilast, 78.75 mg microcrystalline cellulose (diluent), 180.0 mg lactose monohydrate (diluent), 9.0 mg croscarmellose sodium (disintegrant), 2.25 mg magnesium stearate (lubricant), and 12.0 mg Opadry® II (film coating agent).

[0054] This was an open-label, randomized, three-period, six-sequence crossover study in healthy subjects. The study consisted of a screening period, a baseline (day -1), three treatment periods, and a follow-up telephone call. Each treatment period was four days in duration (days 1 to 4) with a five-day washout period between doses.

[0055] After a screening period (days -21 to -2), eligible subjects were admitted to the study center on day -1 of treatment period 1 for baseline assessments. On day 1 of treatment period 1, subjects were randomly assigned to one of six treatment administration sequences:

[0056] [Table 1]

[0057] On day 1 of each treatment period, subjects received a single 30 mg oral dose of apremilast according to one of the following treatment dosing sequences: Treatment A: a single oral dose of apremilast 30 mg tablet under fasting conditions; Treatment B: a single oral dose of apremilast 30 mg oral suspension formulation (6 mL) under fasting conditions; and Treatment C: a single oral dose of apremilast 30 mg oral suspension formulation (6 mL) under fed conditions. Subjects fasted overnight for at least 10 hours prior to dosing of Treatments A and B. Food and drink were prohibited for at least 4 hours after dosing.

[0058] For Treatment C, after an overnight fast of at least 10 hours, all subjects consumed a high-fat meal. A standard high-fat breakfast was identical or equivalent to 2 fried eggs, 2 slices of bacon, 2 slices of buttered toast or bread, 4 ounces of hash brown potatoes, and 8 ounces of whole milk. The entire meal was consumed within 20-25 minutes of being served, and dosing was administered 30 minutes (± 5 minutes) after the start of the meal. No food or drink was permitted for at least 4 hours after dosing.

[0059] All treatments were administered with approximately 240 mL of noncarbonated room temperature water. For all treatments, water was allowed as needed, except 1 hour before and 1 hour after drug administration (except for water given IP). Lunch, dinner, and snacks were provided approximately 4, 9, and 13 hours after dosing, respectively.

[0060] Each subject was asked to rate the aftertaste of the study drug after administration of Treatments B and C and before administration of 240 mL of noncarbonated ambient water.

[0061] Subjects were admitted to the study center from day -1 of treatment period 1 to day 4 of treatment period 3, thus including a 5-day washout between doses. All subjects were discharged from the study center on day 4 of treatment period 3 after completion of all required study treatments. A follow-up call with each subject was made approximately 4 days (± 2 days) after discharge from the study center.

[0062] Blood samples for measurement of apremilast concentrations were collected at the following time points during each treatment period: pre-dose (0 hours) and 0.5, 1, 1.5, 2, 3, 5, 8, 12, 24, 36, 48, 60, and 72 hours post-dose.

[0063] The following PK parameters were derived for apremilast by noncompartmental analysis. Actual sampling time was used as the PK parameter: AUC 0-∞ , AUC 0-t , C max , T max , t 1 / 2 ,CL / F,V z Used to calculate / F and F.

[0064] Software used for data analysis and data presentation included Phoenix™ WinNonlin® version 6.4 (Pharsight Corp., St. Louis, Missouri) and SAS version 9.3 (SAS Institute Inc., Cary, North Carolina).

[0065] To assess the bioavailability between apremilast oral suspension and tablet formulations and the effect of food on the apremilast oral suspension formulation, analysis of variance models with treatment, sequence, and period as fixed effects and subject nested within sequence as a random effect were used to evaluate natural log-transformed AUC and C max Geometric means and percentage ratios of the geometric means (Treatment B / Treatment A and Treatment C / Treatment B) are presented with the 95% confidence intervals (CI) of the ratios.

[0066] T max Non-parametric analysis was used to calculate the median differences between treatments (treatment B vs. treatment A and treatment C vs. treatment B). Medians, median differences, and 90% CIs for median differences were obtained from the Hodges-Lehman estimator. p-values ​​were derived from the Wilcoxon signed-rank test.

[0067] All subjects in Treatment A (apremilast oral 30 mg tablet, fasted state) had measurable apremilast plasma concentrations up to 60 hours post-dose (Figures 1 and 2), all subjects in Treatment B (apremilast 30 mg oral suspension, fasted state) had apremilast plasma concentrations throughout the entire sampling period from pre-dose to 72 hours post-dose, and all subjects in Treatment C (apremilast 30 mg oral suspension, fed state) had apremilast plasma concentrations throughout the entire sampling period from pre-dose to 60 hours post-dose (Figures 3 and 4).

[0068] All pharmacokinetic estimates were calculated using actual recorded blood draw times. Plasma pharmacokinetic parameters are summarized in Table 2.

[0069] Under fed conditions, the 30 mg oral suspension formulation exhibited an AUC equivalent to that of fasted conditions and a C max The T max was delayed by a median of 2 to 5 hours after dosing, but this delay is not considered clinically significant.

[0070] [Table 2]

[0071] The oral 30 mg (6 mL) suspension formulation had comparable AUC and C values ​​to apremilast 30 mg tablets (reference) after a single oral dose under fasting conditions. max However, it was about 13% to 15% lower.

[0072] AUC for both single oral bioavailability of 6 mL (30 mg) apremilast oral suspension formulation (test) versus apremilast 30 mg tablet (reference) formulation and food effect on apremilast oral suspension formulation 0-t , AUC 0-∞ , C max and T max The results of the statistical analysis are presented in Table 3. max Analysis of the median differences is presented in Table 4.

[0073] Under fasting conditions, the bioavailability (AUC 0-∞ ) are equivalent because the AUC 0-∞ The 95% confidence interval for the ratio of geometric means was within the 80% to 125% limits, i.e., within the conventional bioequivalence criteria. max was rated approximately 15% lower.

[0074] Effect of food on apremilast oral suspension formulation: AUC between fasted and fed states 0-∞ The ratios of the geometric means shown in Table 3, which are the 95% confidence intervals of the two, were also within the limits of 80% to 125%. Therefore, it achieved the same bioavailability. max was lower compared to fasting conditions.

[0075] T max The median values ​​are shown in Table 3. Under fasting conditions, apremilast 30 mg oral suspension (test) treatment had median values ​​equivalent to apremilast 30 mg tablets (reference) with a difference of 0.25 hours. max The median time to baseline was significantly delayed when compared with apremilast oral suspension in the fasted state, with a median difference of 2.25 hours. max The effect of diet on the 90% CI was statistically significant (p<0.0001).

[0076] [Table 3]

[0077] [Table 4]

[0078] Pharmacokinetics and pharmacodynamics. Under fasting conditions, the overall bioavailability (AUC0-∞ ) was comparable between the 6 mL (30 mg apremilast) oral suspension formulation and the 30 mg tablet in healthy subjects after a single oral dose, whereas C max Under fed conditions, a single dose of 6 mL (30 mg apremilast) oral suspension resulted in bioavailability (AUC 0-∞ ) but had a low C max T max The median AUC was significantly delayed under fed versus fasted conditions, from 2 to 5 hours post-dose. Overall, these results demonstrate that a single dose of the 6 mL (30 mg apremilast) oral suspension had comparable bioavailability (AUC ) to the 30 mg tablet under fasted conditions. 0-∞ ) Food has no clinically meaningful effect on the PK exposure of apremilast following oral administration of a suspension formulation.

[0079] Under fasted or fed conditions, the plasma concentration versus time profiles were similar between the apremilast 30 mg tablet and the 6 mL (30 mg) suspension formulation. Apremilast had a T of approximately 2 hours after administration. max Apremilast was rapidly absorbed, with a median terminal elimination half-life (t 1 / 2 ) was approximately 8 hours and was similar between the test and reference drugs under fasted or fed conditions. 0-∞ ) were comparable between the 6 mL (30 mg apremilast) oral suspension formulation and the 30 mg tablet in healthy subjects after a single oral dose using fasting conditions, whereas C max was about 15% lower.

[0080] Under fasting conditions, a single dose of 6 mL (30 mg apremilast) oral suspension demonstrated bioavailability (AUC 0-∞ ) was achieved, but compared to fasting conditions, C max was low. maxThe median AUC was significantly delayed (by 2.5 hours) under fed conditions compared to fasted conditions. These results indicate that a single dose of the 6 mL (30 mg apremilast) oral suspension formulation resulted in bioavailability (AUC ) comparable to that under fasted conditions. 0-∞ ) but with respect to fasting conditions, max It has been demonstrated that

[0081] Overall, the oral suspension formulation (30 mg apremilast) had pharmacokinetic exposure comparable to the apremilast 30 mg tablet. Thus, these results suggest that the oral suspension formulation can be administered as an interchangeable alternative to the tablet formulation at the same nominal dose in clinical trials, such as in pediatric subjects who are unable to swallow tablets and require lower doses.

[0082] Apremilast was safe and well tolerated following administration of the apremilast oral suspension formulation under fasted and fed conditions and the apremilast tablet formulation under fasted conditions. The incidence of TEAEs was similar following the oral suspension (administered under fasted and fed conditions) and the tablet formulation. The most common drug-related TEAE was diarrhea, followed by constipation, nausea, and headache. Diarrhea, nausea, and headache were also the most frequently reported TEAEs in previous clinical pharmacology studies with apremilast.

[0083] Pharmacokinetics. Under fasting conditions, the overall bioavailability (AUC 0-∞ ) was comparable between the 6 mL (30 mg apremilast) oral suspension formulation and the 30 mg tablet in healthy subjects after a single oral dose, whereas C max Under fed conditions, a single dose of 6 mL (30 mg apremilast) oral suspension resulted in bioavailability (AUC 0-∞ ) but had a low C max T maxThe median AUC was significantly delayed under fed versus fasted conditions from 2 to 5 hours post-dose. Overall, these results demonstrate that a single dose of the 6 mL (30 mg apremilast) oral suspension had comparable bioavailability (AUC 0-∞ ) Food has no clinically meaningful effect on the PK exposure of apremilast following oral administration of a suspension formulation.

[0084] Safety. A single oral dose of 30 mg apremilast was safe and well tolerated in healthy subjects when administered as an oral suspension under fasted and fed conditions or as a tablet under fasted conditions.

[0085] Example 4 This example demonstrates embodiments of the disclosed suspensions. Suspensions 4A, 4B, and 4C were prepared using the processes disclosed herein to provide batches (26 L) of suspension containing different concentrations of paraben preservative (60-80% levels), as shown in Table 5.

[0086] [Table 5]

[0087] The foregoing examples are merely illustrative of embodiments of the disclosed processes described herein and are not intended to limit the disclosed methods. Variations and modifications that are obvious to those skilled in the art are intended to be within the scope and spirit of the present disclosure as defined by the appended claims.

[0088] All references cited in this specification, including publications, patent applications, and patents, are herein incorporated by reference to the same extent as if each reference was individually and specifically indicated to be incorporated by reference and was set forth in its entirety herein.

[0089] The use of the terms "a" and "an" as well as "the" and "at least one" and similar referents with respect to the description of embodiments of the present disclosure (particularly with respect to the claims below) should be construed to encompass both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. The term "at least one" followed by a list of one or more items (e.g., "at least one of A and B") should be construed to mean one item (A or B) selected from the listed items or any combination of two or more of the listed items (A and B), unless otherwise indicated herein or clearly contradicted by context. The terms "comprise," "have," "include," and "contain" should be construed as open-ended terms (i.e., meaning "including, but not limited to"), unless otherwise indicated herein or clearly contradicted by context. The recitation of ranges of values ​​herein is intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated herein as if it were individually recited herein. All methods described herein may be performed in any suitable order, unless otherwise indicated herein or clearly contradicted by context. The use of any examples or exemplary language (e.g., "etc.") provided herein is intended only to better illuminate embodiments of the disclosure, and does not impose limitations on the scope of the disclosure, unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the disclosure.

Claims

1. A suspension for oral administration comprising: a. Apremilast, b. a suspending agent; c. a sweetener; d. one or more of a vehicle, a co-solvent, a buffer, a preservative, or a combination thereof; e. Water and A suspension comprising:

2. 2. The suspension of claim 1, wherein the apremilast is present in the suspension at a total concentration of 3 to 10 mg / mL.

3. 3. The suspension of claim 2, wherein the apremilast is present in the suspension at a total concentration of 5 mg / mL.

4. 4. The suspension of any one of claims 1 to 3, wherein the suspending agent comprises microcrystalline cellulose, sodium carboxymethylcellulose, methylcellulose, ethylcellulose, xanthan gum, xanthin gum, carrageenan; guar gum, locust bean gum, carbomer, magnesium aluminum silicate (Veegum) or combinations thereof.

5. 5. The suspension of claim 4, wherein the suspending agent comprises a blend of microcrystalline cellulose and sodium carboxymethylcellulose (microcrystalline cellulose / sodium carboxymethylcellulose blend) and xanthan gum.

6. 6. The suspension of claim 5, wherein the microcrystalline cellulose / sodium carboxymethyl cellulose blend and xanthan gum are present in a concentration ratio of 3.4:1 to 4:1 or less.

7. 7. The suspension of claim 6, wherein the ratio is 3.7:

1.

8. 8. A suspension according to any one of claims 1 to 7, wherein the suspending agent is present in the suspension at a total concentration of 8.5 mg / mL.

9. The suspension of any one of claims 1 to 8, wherein the sweetener comprises sucrose, sorbitol, aspartame, fructose, lactose or combinations thereof.

10. 10. The suspension of claim 9, wherein the sweeteners include sucrose and sorbitol.

11. 11. The suspension of claim 9 or 10, wherein the sweetener is present in the suspension at a total concentration of up to 500 mg / mL.

12. 12. The suspension of claim 11, wherein the sweetener is present in the suspension at a total concentration of 380 mg / mL.

13. 10. The suspension according to any one of claims 1 to 9, wherein the sweeteners comprise sucrose in a concentration of 150 to 225 mg / mL and sorbitol in a concentration of 150 to 225 mg / mL.

14. 14. The suspension of claim 13, wherein the sweetener comprises sucrose and sorbitol in a one to one concentration ratio.

15. A suspension according to any one of claims 1 to 14, comprising a vehicle.

16. 16. The suspension of claim 15, wherein the vehicle comprises glycerin.

17. 17. The suspension of claim 15 or 16, wherein the vehicle is present in the suspension at a total concentration of from 100 mg / mL to 200 mg / mL.

18. 20. The suspension of claim 17, wherein the vehicle is present at a total concentration of 133 mg / mL.

19. A suspension according to any one of claims 1 to 18, comprising a co-solvent.

20. 20. The suspension of claim 19, wherein the co-solvent comprises propylene glycol.

21. 21. The suspension of claim 19 or 20, wherein the co-solvent is present in the suspension at a total concentration of from 10 mg / mL to 20 mg / mL.

22. 22. The suspension of claim 21 , wherein the co-solvent is present at a total concentration of 14 mg / mL.

23. A suspension according to any one of claims 1 to 22, comprising a buffering agent.

24. 24. The suspension of claim 23, wherein the buffering agent comprises citric acid or a hydrate thereof, a citrate salt, tartaric acid, a tartrate salt, ascorbic acid, an ascorbate salt, phosphoric acid, a phosphate salt, acetic acid, an acetate salt, or a combination thereof.

25. 25. The suspension of claim 24, wherein the buffering agent comprises citric acid monohydrate.

26. 26. The suspension of any one of claims 23 to 25, wherein the buffering agent is present in the suspension at a total concentration of from 1 mg / mL to 5 mg / mL.

27. 27. The suspension of claim 26, wherein the buffering agent is present at a total concentration of 1.8 mg / mL.

28. A suspension according to any one of claims 1 to 27, comprising a preservative.

29. 30. The suspension of claim 28, wherein the preservative comprises methylparaben, propylparaben, or a combination thereof.

30. 30. The suspension of claim 29, wherein the preservatives include methylparaben and propylparaben.

31. 31. The suspension of claim 30, wherein the methylparaben and propylparaben are present in a concentration ratio of 9:

1.

32. 32. A suspension according to any one of claims 28 to 31, wherein the preservative is present in the suspension in a total concentration of from 1 mg / mL to 2.5 mg / mL.

33. 33. The suspension of claim 32, wherein the preservative is present in a total concentration of 1.7 mg / mL.

34. 33. A suspension according to any one of claims 30 to 32, wherein methylparaben is present in a concentration of 0.9 mg / mL or more and propylparaben is present in a concentration of 0.1 mg / mL or more.

35. A suspension for oral administration comprising a) apremilast, b) a blend of microcrystalline cellulose and sodium carboxymethylcellulose, c) xanthan gum, d) sucrose, e) sorbitol, f) glycerin, g) propylene glycol, h) citric acid monohydrate, i) methylparaben, j) propylparaben, and k) water.

36. 36. The suspension of claim 35, comprising: a) 5 mg / mL apremilast, b) 6.7 mg / mL of the blend of microcrystalline cellulose and sodium carboxymethylcellulose, c) 1.8 mg / mL xanthan gum, d) 190 mg / mL sucrose, e) 190 mg / mL sorbitol, f) 133 mg / mL glycerin, g) 14 mg / mL propylene glycol, h) 1.8 mg / mL citric acid monohydrate, i) 1.5 mg / mL methylparaben, j) 0.17 mg / mL propylparaben, and k) water.

37. 36. The suspension of claim 35, comprising: a) 5 mg / mL apremilast, b) 6.7 mg / mL of the blend of microcrystalline cellulose and sodium carboxymethylcellulose, c) 1.8 mg / mL xanthan gum, d) 190 mg / mL sucrose, e) 190 mg / mL sorbitol, f) 133 mg / mL glycerin, g) 14 mg / mL propylene glycol, h) 1.8 mg / mL citric acid monohydrate, i) 0.9 mg / mL methylparaben, j) 0.10 mg / mL propylparaben, and k) water.

38. 36. The suspension of claim 35, comprising: a) 5 mg / mL apremilast, b) 6.7 mg / mL of the blend of microcrystalline cellulose and sodium carboxymethylcellulose, c) 1.8 mg / mL xanthan gum, d) 190 mg / mL sucrose, e) 190 mg / mL sorbitol, f) 133 mg / mL glycerin, g) 14 mg / mL propylene glycol, h) 1.8 mg / mL citric acid monohydrate, i) 1.1 mg / mL methylparaben, j) 0.12 mg / mL propylparaben, and k) water.

39. 36. The suspension of claim 35, comprising: a) 5 mg / mL apremilast, b) 6.7 mg / mL of the blend of microcrystalline cellulose and sodium carboxymethylcellulose, c) 1.8 mg / mL xanthan gum, d) 190 mg / mL sucrose, e) 190 mg / mL sorbitol, f) 133 mg / mL glycerin, g) 14 mg / mL propylene glycol, h) 1.8 mg / mL citric acid monohydrate, i) 1.2 mg / mL methylparaben, j) 0.14 mg / mL propylparaben, and k) water.

40. 40. The suspension of any one of claims 1 to 39, which, when administered to a patient under fasting conditions, has an AUC that is 90% to 110% of the AUC of an immediate release oral apremilast tablet of equivalent apremilast content.

41. 41. A method of treating a patient suffering from a disease or disorder ameliorated by inhibiting PDE4, comprising administering to said patient a suspension according to any one of claims 1 to 40.

42. 42. The method of claim 41, wherein the disease or disorder is psoriasis, psoriatic arthritis or Behcet's disease.

43. 43. The method of claim 41 or 42, wherein the patient is a pediatric patient.

44. 41. A packaged suspension comprising the suspension of any one of claims 1 to 40, a bottle and a stopper.

Citation Information

Patent Citations

  • Nanosuspensions of poorly soluble drugs prepared by microfluidic processing

    JP2013510855A